WebDoctor Encyclopedia

Adnexal carcinomas Skin

Spiradenocarcinoma

Spiradenocarcinoma is a rare skin cancer that usually develops inside a long-standing benign lump called a spiradenoma. A sudden change in an old lump is the main warning sign. Wide surgical removal is the core treatment, and low-grade tumours usually do well.

Medically reviewed Last reviewed October 20, 2026

What is spiradenocarcinoma?

Spiradenocarcinoma is a rare skin cancer that develops from structures linked to the sweat glands. In most cases it arises within a spiradenoma, a benign sweat gland tumour that may have been present for many years. It is also known as malignant spiradenoma or malignant eccrine spiradenoma.

Spiradenocarcinoma is one of the adnexal carcinomas, a family of cancers that start in the skin’s “appendages”, such as sweat glands and hair follicles. It is extremely uncommon. A study of the large US cancer registry found only 90 cases over twenty years (Martineau et al., 2023).

The typical story is a small lump that has been present for years and then starts to grow quickly, change colour, become painful or bleed (Staiger et al., 2017). The disease mainly affects people around 60, and men and women are affected in similar numbers.

Its behaviour varies. Low-grade tumours, which are more common, usually stay local and are cured by surgery. High-grade tumours are more aggressive and can spread to lymph nodes, lungs, bones and liver. The main treatment is wide surgical removal, with lymph node surgery when needed.

1. Key facts at a glance

Feature Details
Type of cancer Malignant adnexal (sweat gland-related) skin tumour
Also called Malignant spiradenoma; malignant eccrine spiradenoma
How common Extremely rare
Typical age Around 60; usually adults
Sex Men and women equally
Typical history A long-standing lump that suddenly grows
Main sites Head, neck, trunk and limbs; anywhere with sweat glands
Main treatment Wide local excision; lymph node surgery if involved
Outlook Good for low-grade tumours; poorer for high-grade tumours

2. Types of spiradenocarcinoma

By grade

Grade Features Behaviour
Low grade Cells only mildly abnormal; some residual benign pattern Mostly local; good outlook
High grade Very abnormal cells, many mitoses, necrosis More likely to recur, spread and cause death

Low-grade tumours have been reported more than three times as often as high-grade ones, but the high-grade tumours carry most of the risk (Staiger et al., 2017).

Tumour Description
Spiradenoma Benign; a well-defined, often painful nodule
Atypical spiradenoma Shows some worrying features but not definite cancer
Cylindroma Benign related tumour, often on the scalp
Cylindrocarcinoma Malignant counterpart of cylindroma
Spiradenocylindrocarcinoma Contains features of both

How it compares with other skin cancers

Feature Spiradenocarcinoma Basal cell carcinoma Squamous cell carcinoma
Frequency Extremely rare Very common Common
Usual history Old lump that changes Slowly growing pearly lump Scaly, growing lump or sore
Link with sun Weak Strong Strong
Spread Possible, especially high grade Very rare Uncommon
Main treatment Wide excision Excision, Mohs and other options Excision

3. Causes and risk factors

The cause is not fully understood. Most spiradenocarcinomas appear to develop from a benign spiradenoma that has undergone malignant change (Wagner et al., 2021).

Factor Notes
Long-standing spiradenoma The main risk factor; often present for many years
Older age Most cases occur after 50
CYLD cutaneous syndrome (Brooke-Spiegler syndrome) Inherited condition with many cylindromas, spiradenomas and trichoepitheliomas; higher risk of malignant change
Fair skin More common in white people in published series

People with CYLD cutaneous syndrome often have multiple skin lumps and need regular skin checks for any that change.

Skin appendages and their cancers

Skin structure Normal role Examples of cancers
Eccrine sweat glands Produce watery sweat for cooling, all over the body Porocarcinoma, hidradenocarcinoma
Apocrine glands Found mainly in the armpits and groin Apocrine carcinoma, extramammary Paget disease
Hair follicles Produce hair Pilomatrix carcinoma, trichilemmal carcinoma
Sebaceous glands Produce oily sebum Sebaceous carcinoma
Uncertain (spiradenoma family) Related to sweat gland structures Spiradenocarcinoma, cylindrocarcinoma

All of these cancers are rare, and they are often diagnosed only after a lump has been removed and examined.

CYLD cutaneous syndrome

This inherited condition is caused by a change in the CYLD gene. People with it develop many benign skin tumours, often on the scalp and face, beginning in early adulthood. The tumours include cylindromas, spiradenomas and trichoepitheliomas.

Each one has a small risk of becoming malignant, so regular skin reviews and prompt removal of any lump that changes are recommended. Relatives may be offered genetic testing.

4. How does it look

On the skin

Feature Description
Shape A firm nodule or lump, sometimes with several lumps together
Colour Skin-coloured, pink, red, bluish or purple
Surface Smooth at first; may ulcerate or bleed
Size Often 1-5 cm; can become larger
Change A sudden increase in size of an old lump
Tenderness Spiradenomas are often painful, and so may the carcinoma be

On scans

Ultrasound or MRI shows how deep the tumour extends. PET-CT and CT are used to look for spread, especially for high-grade tumours (Staiger et al., 2017).

Under the microscope

Feature Description
Background Often a residual benign spiradenoma
Transition An abrupt change from benign to malignant areas
Cell pattern Loss of the normal two-cell population, replaced by uniform abnormal cells
Mitoses Atypical dividing cells
Necrosis Present in some tumours
Stains Higher Ki-67 and p53 in malignant areas

These features help pathologists distinguish spiradenocarcinoma from an atypical but benign spiradenoma (Huang et al., 2019).

5. Symptoms

Common symptoms

  • A lump that has been present for years and starts to grow quickly
  • A change in colour or appearance of an old lump
  • Pain or tenderness
  • Bleeding or ulceration

Less common symptoms

Symptom What it may mean
Lumps in nearby lymph nodes Regional spread
Cough or breathlessness Lung spread
Bone pain Bone spread
Tiredness and weight loss Advanced disease

When to seek medical advice

See a doctor about any skin lump that changes, especially one that has been present for a long time and then grows, bleeds or becomes painful. Prompt removal and examination under the microscope is the only way to be sure.

6. Diagnosis

Test Purpose
Skin examination and dermoscopy Assesses the lump and surrounding skin
Biopsy or excision Confirms the diagnosis and grade
Lymph node examination and ultrasound Checks nearby nodes
MRI Defines the depth and extent of the tumour
PET-CT or CT Looks for spread, especially with high-grade tumours
Fine needle aspiration of nodes If nodes are enlarged

Because the tumour is rare and can resemble other skin cancers, the slides are often reviewed by a specialist dermatopathologist.

Why a pathologist’s review matters

Benign spiradenomas can contain areas that look unusual under the microscope. Telling an atypical spiradenoma from a true spiradenocarcinoma, and then grading the cancer, requires careful assessment of the whole specimen. The pathologist looks for an abrupt switch from benign to malignant tissue, loss of the two normal cell types, abnormal dividing cells and dead tissue. Special stains such as Ki-67 and p53 can highlight the malignant areas (Huang et al., 2019).

The final grade guides how much further treatment and imaging are needed.

Staging

There is no staging system specific to spiradenocarcinoma. Doctors usually describe:

Element Meaning
Local disease Confined to the skin and tissue beneath
Regional disease Spread to nearby lymph nodes
Distant disease Spread to lungs, bones, liver or other organs

In the US registry, regional or distant spread at diagnosis was uncommon, together accounting for only about 5% of cases (Martineau et al., 2023).

7. Treatment

Surgery

Procedure Notes
Wide local excision The main treatment; margins of about 1 cm or more are often recommended
Mohs micrographic surgery Used in some centres, especially on the face
Sentinel lymph node biopsy Considered in selected high-risk cases
Lymph node dissection If nodes contain cancer
Reconstruction Skin graft or flap for larger wounds

A literature review recommended wide local excision aiming for margins of at least 1 cm, with node surgery decided case by case (Wagner et al., 2021). Most patients in the US registry were treated with surgery alone (Martineau et al., 2023).

Radiotherapy

Situation Role
Close or positive margins May reduce local recurrence
Lymph node spread After node surgery
Unresectable or painful disease For symptom control

Drug treatment

For spread to distant organs there is no standard drug treatment. Chemotherapy has been used with limited success. Immunotherapy (PD-1 inhibitors) has produced responses in individual reported cases, and clinical trials may be considered.

Side effects

Treatment Possible side effects
Surgery Scarring, wound infection, numbness
Lymph node surgery Swelling (lymphoedema), stiffness
Radiotherapy Skin redness, tiredness, hair loss in the treated area
Immunotherapy Rash, diarrhoea, inflammation of organs

What treatment involves day to day

Stage What to expect
Excision Usually a day case under local or general anaesthetic
Wound care Dressings for 1-2 weeks; stitches removed at 1-2 weeks
Node surgery A short hospital stay and a drain
Radiotherapy Weekday sessions for several weeks if needed

8. Outlook (prognosis)

Estimates of outlook vary widely between data sources.

Source Findings
US registry (90 cases) Five-year disease-specific survival about 96%; overall survival about 76% (Martineau et al., 2023)
Literature review (182 cases) Local recurrence about 21%, metastasis about 37%, death about 19% (Wagner et al., 2021)

The difference probably reflects the fact that published case reports tend to describe unusual, aggressive cases. The registry data suggest that the risk of dying from the disease is lower than once thought (Martineau et al., 2023).

Factor Effect
Low grade Better outlook
High grade Higher risk of recurrence and death
Clear margins Lower risk of recurrence
Cancer-free lymph nodes Better outlook
Distant spread Poor outlook

9. Follow-up

Follow-up Purpose
Clinic review every 3-6 months at first Checks the scar and lymph nodes
Imaging CT or PET-CT, particularly for high-grade tumours
Skin checks Especially in CYLD cutaneous syndrome
Longer-term reviews Once or twice a year after the first few years

Experts recommend frequent follow-up with imaging in the early years, particularly for high-grade tumours (Staiger et al., 2017).

10. Living with spiradenocarcinoma

  • Check your scar and nearby lymph nodes each month
  • Report new lumps, cough or bone pain promptly
  • Protect your skin from the sun, as for any skin cancer
  • Look after your wound and keep it clean while it heals
  • Ask about genetic advice if you have many similar skin lumps or a family history
  • Keep a photo record of any other skin lumps so changes are easier to spot
  • Seek support from skin cancer and rare cancer charities

11. Frequently asked questions

Question Answer
Did my old lump turn into cancer? Most spiradenocarcinomas arise in an old benign spiradenoma
Is it a sweat gland cancer? Yes, it is related to sweat gland structures
Can it spread? Yes, especially high-grade tumours
Will I need chemotherapy? Usually not; surgery is the main treatment
Is it inherited? Usually not, except with CYLD cutaneous syndrome
Can it come back after surgery? Yes, particularly if margins were close, which is why regular checks matter
Is it caused by the sun? No strong link has been shown
Why do sources give different survival figures? Case reports tend to describe severe cases, while registries include milder ones
Will I have a large scar? It depends on the size and site; reconstruction can help
How long will follow-up last? Usually at least 5 years, with more frequent visits at first

12. Questions to ask your care team

  • Is my tumour low grade or high grade?
  • Were the margins clear, and how wide were they?
  • Do I need lymph node tests or surgery?
  • Should I have a PET-CT or other scans?
  • Do I need radiotherapy?
  • How often should I come for follow-up?
  • Has my biopsy been reviewed by a specialist skin pathologist?
  • Should my family be offered any tests?

Resources

  1. Huang, A. et al. (2019) ‘Histological findings and pathologic diagnosis of spiradenocarcinoma: a case series and review of the literature’, Journal of Cutaneous Pathology, 46(4), pp. 243-250.
  2. Martineau, J. et al. (2023) ‘Spiradenocarcinoma: SEER study of epidemiology, survival, and treatment options’, Journal of Clinical Medicine, 12(5), 2045.
  3. Staiger, R.D. et al. (2017) ‘Spiradenocarcinoma: a comprehensive data review’, American Journal of Dermatopathology, 39(10), pp. 715-725.
  4. Wagner, K. et al. (2021) ‘Challenges in diagnosis and management of a spiradenocarcinoma: a comprehensive literature review’, ANZ Journal of Surgery, 91(10), pp. 1996-2001.

Prepared by the editorial team, October 2026.